Advancing Bioconjugates with Novel Formats & Payloads

Spotlighting Innovation in Novel Targeting Formats & Payloads to Enhance Delivery, Overcome Payload Resistance and Expand Therapeutic Reach

Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as well as the exploration of non-oncology indications.

The 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored, what benefit each approach has and the directions the space is heading.

Attendees gain valuable competitive insight into emerging technologies, early data, and the rationale behind each approach, from established pharma leaders to the newest biotech entrants. Whether your goal is to benchmark your pipeline, explore partnership opportunities, or stay ahead of fast-moving design trends, this summit offers a front-row seat to the next wave of conjugate innovation.

Participating in a small conference where you could get to know many of those working in the same or closely related fields was great. It was also great to see a wide range of conjugate formats discussed.

Prelude Therapeutics

Prelude Therapeutics Testimonial - 5th Novel Conjugates Summit

The organizer has selected the topics and speakers very thoughtfully, which allowed broad enough but at the same time very focused and engaging conversations among attendees.

Salubris Biotherapeutics

Salubris Biotherapeutics testimonial - 5th Novel Conjugates Summit

There were many interesting topics, so I learned a lot. This summit brought together key people in this field, so it was also effective in expanding my network.

Daiichi Sankyo

Daiichi Sankyo - 5th Novel Conjugates Summit

Explore the Full Event Guide

  • 20+ companies showcasing the rationale and data behind their approach in novel conjugate development
  • 5+ pharma search & evaluation experts discussing partnerships within novel conjugates
  • 6+ networking hours for learning from others in the space and forming brand new connections
  • 2 deep dive workshops for cross-modality collaboration and optimising the design of novel conjugate drugs
  • A poster session for allowing delegates to showcase cutting-edge work to the audience
Full Event Guide - 5th Novel Conjugates Summit

More than a meeting…

150+

Attendees from across the bioconjugate field

25+

Expert
Speakers

2

Cross-Modality Interactive Workshop Sessions

3

Days of Pioneering Bioconjugate Content

Unlimited Opportunities for Networking & Knowledge Sharing

Official Partners

Expertise Partners

Hosting Partners

Attending Companies Include

AstraZeneca - 5th Novel Conjugates Summit
Johnson & Johnson - 5th Novel Conjugates Summit
Daiichi Sankyo - 5th Novel Conjugates Summit
Merck - 5th Novel Conjugates Summit
BiVictrix - 5th Novel Conjugates Summit
Bolt Biotherapeutics - 5th Novel Conjugates Summit
Sutro Biopharma - 5th Novel Conjugates Summit
Accutar Biotechnology - 5th Novel Conjugates Summit
Antikor Logo - 5th Novel Conjugates Summit
Explore The Agenda - 5th Novel Conjugates Summit
Explore the Agenda

Discover the latest differentiated approaches in bioconjugate design, from next-generation payloads to novel targeting formats. Gain deep insights through data-rich case studies, interactive workshops, and strategic panel discussions.

Partner With Us - 5th Novel Conjugates Summit
Partner With Us

Showcase your capabilities alongside leading CDMOs, technology providers, and biopharma innovators shaping the future of ADCs and next-generation conjugates. Position your brand at the center of industry-defining partnerships.

Conjugates Experts - 5th Novel Conjugates Summit
Join Conjugate Experts

Connect with the scientists, business developers, and external innovation leaders driving the evolution of targeted drug conjugates, and build the collaborations that will shape tomorrow’s precision therapeutics.